UnitedHealthcare (UMR) updated its Respiratory Interleukins policy covering Cinqair®, Fasenra®, and Nucala®, effective April 1, 2026. The March 2026 bulletin lists the entry as “Status = Updated,” but the excerpt provides no details on changes to clinical criteria, prior authorization, coding, dosing, age limits, or indications. This entry is part of a broader set of medical benefit drug policy updates effective April 1, 2026, so providers should expect substantive policy language to be available in the payer’s policy library. Consult UnitedHealthcare/UMR’s full respiratory interleukins policy for the specific coverage and utilization management updates.
April 1, 2026 Revision: `Respiratory Interleukins (Cinqair®, Fasenra®, & Nucala®)` Marked as Updated
The March 2026 bulletin indicates an update specific to Respiratory Interleukins (Cinqair®, Fasenra®, & Nucala®) with an effective date of Apr. 1, 2026. The entry for these agents is labeled as "Status = Updated," distinguishing it from many other line items in the same bulletin that are labeled "Revised" or "Updated." The update is listed alongside multiple other drug policy changes effective on Apr. 1, 2026, but the source text provides no further detail about the nature of the clinical or administrative changes to coverage for these interleukin-targeting biologics.
The document presents this as part of a consolidated set of medical benefit drug policy updates distributed by UMR for UnitedHealthcare. The only explicit facts in the source are the agent group (Cinqair®, Fasenra®, Nucala®), the status (Updated), and the effective date (Apr. 1, 2026). No specific edits, criteria, or language from the updated respiratory interleukins policy are included in the source text.
Context Within Broader Apr. 1, 2026 Medical Benefit Drug Policy Updates
Within the same bulletin, multiple distinct drug policy topics are listed with effective date Apr. 1, 2026, indicating a broad update cycle. Items shown as revised include Complement C5 Inhibitors, Denosumab, FcRn Blockers, Oncology Medication Clinical Coverage, Ophthalmologic Vascular Endothelial Growth Factor (VEGF) Inhibitors, Provider Administered Drugs - Site of Care, Somatostatin Analogs, and Uplizna® (Inebilizumab-Cdon). Evkeeza® (Evinacumab-Dgnb) is shown as "Updated." The respiratory interleukins entry appears among these, signifying it is part of a broader set of contemporaneous policy actions implemented by UnitedHealthcare/UMR.
Scope of Products Listed Under the Respiratory Interleukins Entry
The source text identifies the specific products impacted by the respiratory interleukins entry: Cinqair®, Fasenra®, and Nucala®. These three agents are grouped under the heading "Respiratory Interleukins," suggesting the update applies to interleukin-targeting biologics used in respiratory indications. The bulletin does not include any amended coverage criteria, prior authorization requirements, coding (CPT/HCPCS), dosing, age limits, or indication-specific language for these products in the excerpt provided.
Because the published snippet is a summary listing, it functions primarily as a notification that the detailed policy content has been updated elsewhere in the payer's policy library effective Apr. 1, 2026. The summary itself contains no clinical details or definitional changes for Cinqair®, Fasenra®, or Nucala®.
Bulletin Format and Nature of Information Provided for the Respiratory Interleukins Entry
The bulletin is titled "UMR Medical Policy Update Bulletin: March 2026," and the respiratory interleukins line is one of several entries presented in a compact, enumerated format. Each line follows a consistent structure: policy topic, status (e.g., "Revised", "Updated"), and effective date. For the respiratory interleukins item, that structure is preserved: Respiratory Interleukins (Cinqair®, Fasenra®, & Nucala®), Status = Updated. Respiratory Interleukins (Cinqair®, Fasenra®, & Nucala®), Effective Date = Apr. 1, 2026.
The format implies that stakeholders are being alerted to the administrative fact of an update rather than being provided the substantive policy language in the bulletin excerpt. The absence of additional descriptive text in the source means any further interpretation of changes to coverage, utilization management, or clinical criteria cannot be sourced from this document alone.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.